Eryılmaz Ertugrul, Canpolat Cengiz
Department of Pediatrics, Division of Pediatric Hematology and Oncology, Acibadem Maslak Hospital.
Department of Pediatric Hematology and Oncology, Acibadem Kozyatagi Hospital, Acıbadem University School of Medicine, Istanbul, Turkey.
Onco Targets Ther. 2017 Jul 4;10:3299-3306. doi: 10.2147/OTT.S126368. eCollection 2017.
Achieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.
在儿童白血病治疗中实现更低的发病率和更高的生存率，已成为现代肿瘤学成功的典范。然而，在大量儿童白血病幸存者中，无论是急性淋巴细胞白血病还是急性髓系白血病（AML），都会出现严重的长期健康并发症。此外，15%的急性淋巴细胞白血病患者治疗失败，儿童AML的治疗失败率更高。在过去几十年里，经过充分测试并对治疗队列进行统计分析的实验，催生了新的药物，作为既定治疗方法的替代或补充，这些新药物显示出高生存率和/或更低的发病率。本综述概述了儿童白血病治疗的更佳实践。
